WEX Reconstitutes Scientific Advisory Board

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 25, 2007) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) today announces that the Company has reconstituted its Scientific Advisory Board and appointed an outstanding group of physicians and scientists to its new Scientific Advisory Board. These five advisory board members will provide WEX senior management with scientific and medical advice on the Company's drug development plans and strategies.

"We are privileged to have assembled such a distinguished board," said Dr. Edge Wang, President and CEO of the Company. "As we move forward with our drug development plans, we will undoubtedly benefit from the advice and guidance of such an esteemed group of experts."

The new WEX Scientific Advisory Board will include:

Charles Berde, MD, PhD, is the Sara Page Mayo Chair, Chief of the Division of Pain Medicine in the Department of Anesthesiology, Perioperative and Pain Medicine at Children's Hospital Boston and a Professor of Anaesthesia (Pediatrics) at Harvard Medical School. Dr Berde's laboratory and translational research program focuses on local anesthetic mechanisms and the development of novel local anesthetic formulations. His clinical research focuses on analgesic pharmacology in children and on treatments for chronic pain in children. Dr. Berde has received several awards and honors for his pioneering work in pediatric pain relief, including the 2001 Jeffrey Lawson Award from the American Pain Society and the 2003 Scientific Achievement Award of the Reflex Sympathetic Dystrophy Syndrome Association. He was profiled as one of Time Magazine's "Heroes in Medicine" in 1997. He has served as the President of the Pediatric Special Interest Group of the International Association for the Study of Pain, and currently serves on the editorial boards of Pain and Regional Anesthesia and Pain Medicine. Dr. Berde received an MD and PhD (Biophysics) from Stanford University School of Medicine. He completed an internship and residency in pediatrics at Children's Hospital Boston, a residency in anesthesia at Massachusetts General Hospital, and a fellowship in pediatric anesthesia at Children's Hospital Boston. In 1985, along with Dr. Navil Sethna and Dr. Bruce Masek, Dr. Berde founded the world's first multidisciplinary pain management program for children. The Pain Treatment Service at Children's Hospital Boston remains the most clinically active pediatric pain program in the world.

Howard M. Cohen, MD, is an Adjunct Assistant Professor at the Graduate School of the University of Texas at Arlington. Dr. Cohen is an associate of PRIDE (Productive Rehabilitation Institute of Dallas for Ergonomics), the pain research and rehabilitation institute that first developed the concept of functional restoration, now a worldwide standard of care. He is certified by the American Board of Psychiatry and Neurology in Pain Medicine, Psychosomatic Medicine, Psychiatry, Geriatric Psychiatry, and Addiction Psychiatry. He is a Diplomate of the American Board of Pain Medicine and a Fellow of the American College of Pain Medicine. Dr. Cohen has published in the fields of pain medicine and addiction, supervised clinical research, and has consulted for numerous pharmaceutical companies.

Patrick du Souich, MD, PhD, is Professor and Chairman of the Department of Pharmacology in the Faculty of Medicine at the University of Montreal and Chairman of the Clinical Division of the International Union for Basic and Clinical Pharmacology (IUPHAR). Besides numerous awards, Dr. du Souich has over 225 publications to his credit and has presented over 211 papers at national and/or international meetings. He has received numerous clinical appointments and he is Staff member of Department of Medicine, Division of Clinical Pharmacology at the Centre Hospitalier de l'Universite de Montreal, Hopital Hotel Dieu de Montreal. Dr. du Souich is also a member of several national and international editorial boards such as the Canadian Journal of Physiology and Pharmacology, Therapie, the British Journal of Pharmacology and Acta Sinica Pharmacologica. His research focuses on the effect of disease on the kinetics, dynamics and biotransformation of drugs.

KyungMann Kim, PhD, CCRP, is Professor of Biostatistics and Statistics and Associate Chair of the Department of Biostatistics and Medical Informatics at the University of Wisconsin-Madison and Director of Biostatistics Shared Resource at the University of Wisconsin Comprehensive Cancer Center. He is a Fellow of the American Statistical Association and is recognized nationally and internationally for his contributions in statistical methods for clinical trials and clustered data analysis and in clinical oncology research and has published extensively in statistical methods for clinical trials and in cancer clinical trials. He serves on a number of data and safety monitoring boards of U.S. government- and industry-sponsored clinical trials in many disease areas and on the Human Studies Review Board of the U.S. Environmental Protection Agency.

Edward M. Sellers, MD, PhD, is President and CEO of DecisionLine Clinical Research Corporation. Dr. Sellers is a graduate of the University of Toronto, Faculty of Medicine (MD 1965) and Harvard University (PhD 1971, Pharmacology) and is a certified specialist in Internal Medicine (FRCPC 1972, ABIM 1972). He is a Professor Emeritus of Pharmacology, Medicine and Psychiatry at the University of Toronto and is an internationally recognized scientist having published more than 600 articles, chapters and monographs. Dr. Sellers is a member of numerous national and international editorial boards, governmental advisory committees and international organizations including the World Health Organization Expert Advisory Committee on Drug Dependence. Dr. Sellers has been President of the American Society for Clinical Pharmacology and Therapeutics, the Canadian Society for Clinical Pharmacology and the College on the Problems of Drug Dependence. He has received numerous awards, including the Rawls-Palmer Award for Progress in Medicine of the American Society for Clinical Pharmacology and Therapeutics.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward-Looking Statements and Information

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.